The reinforcing properties of nicotine depend partly on cholinergic projections from the pedunculopontine tegmental (PPTg) and laterodorsal tegmental (LDTg) nuclei to midbrain dopamine neurons in the ventral tegmental area (VTA) and substantia nigra pars compacta (SNc). Neuronal activation was investigated using Fos expression in these areas following acute (0, 0.1, 0.4, 0.8mg/kg) or chronic systemic nicotine (0, 0.1, 0.4, 0.8, 1.0mg/kg given once per day for 5 days). We also examined co-localization of Fos expression in bNOS and TH positive neurons to determine what populations of neurons were activated by nicotine. Acute nicotine resulted in dose related Fos expression, with the biggest increase seen after 0.4mg/kg nicotine, but no co-localization occurred with bNOS in the PPTg/LDTg. Surprisingly, nicotine also failed to activate midbrain dopamine neurons. After animals were sensitized to nicotine there was a similar dose response curve in Fos expression, but the biggest increase was seen after 0.8mg/kg nicotine. Chronic nicotine, like acute, also preferentially activated non-cholinergic neurons in the LDTg and PPTg and non-dopamine neurons in the SNc and VTA. Further experiments looked at the mechanisms of Fos expression after nicotine administration. Fos expression in the LDTg/PPTg and SNc/VTA was suppressed after d-amphetamine, despite an increase in locomotor activity, suggesting that the increased Fos expression after chronic nicotine was not simply due to the locomotor activating effects of sensitized nicotine. Blocking autoreceptors in the dopaminergic midbrain by haloperidol pre-treatment did not increase Fos expression in dopamine neurons indicating that the inhibitory mechanism was not dependent on local autoreceptors. Novel methods of visualising and lesioning GABA neurons in the mesopontine tegmentum and midbrain were also examined. The data suggest that the mechanisms by which dopamine is involved in the pharmacological actions of passively administered nicotine are more complex than was first thought and that the role of non-dopamine neurons in the VTA (possibly GABA or glutamate containing) are also important.

Nicotine has multiple behavioral effects as a result of its action in the central nervous system. Nicotine strengthens the behaviors that lead to nicotine administration (primary reinforcement), and this effect of nicotine depends on mesotelencephalic systems of the brain that are critical to goal directed behavior, reward, and reinforcement. Nicotine also serves as a ‘reinforcement enhancer’ – drug administration enhances behaviors that lead to other drug and nondrug reinforcers. Although the reinforcement enhancing effects of nicotine may promote tobacco use in the face of associated negative health outcomes, the neuroanatomical systems that mediate this effect of nicotine have never been described. The ventral tegmental area (VTA) is a nucleus that serves as a convergence point in the mesotelencephalic system, plays a substantial role in reinforcement by both drug and nondrug rewards and is rich in both presynaptic and postsynaptic nicotinic acetylcholine receptors (nAChRs). Therefore, these experiments were designed to determine the role of the VTA and nAChR subtypes in the reinforcement enhancing effect of nicotine. Transiently inhibiting the VTA with a gamma amino butyric acid (GABA) agonist cocktail (baclofen and muscimol) reduced both primary reinforcement by a visual stimulus and the reinforcement enhancing effect of nicotine, without producing nonspecific suppression of activity. Intra-VTA infusions of a high concentration of mecamylamine a nonselective nAChR antagonist, or methylycaconitine, an α7 nAChR antagonist, did not reduce the reinforcement enhancing effect of nicotine. Intra-VTA infusions of a low concentration of mecamylamine and dihydro-beta-erythroidine (DHβE), a selective antagonist of nAChRs containing the *β2 subunit, attenuated, but did not abolish, the reinforcement enhancing effect of nicotine. In follow-up tests replacing systemic nicotine injections with intra-VTA infusions (70mM, 105mM) resulted in complete substitution of the reinforcement enhancing effects – increases in operant responding were comparable to giving injections of systemic nicotine. These results suggest that *β2-subunit containing nAChRs in the VTA play a role in the reinforcement enhancing effect of nicotine. However, when nicotine is administered systemically these reinforcement enhancing effects may depend on the action of nicotine at nAChRs in multiple brain nuclei.

Multiple interactions between dopamine (DA), glutamate, and nitric oxide (NO) in mesolimbic and corticostriatal circuits suggest that NO may play a critical role in cocaine-induced behavioral and neural plasticity. Clinical and preclinical studies have revealed that females and adolescents display unique vulnerabilities to the behavioral and neurochemical effects of cocaine as a result of sex-dependent and ontogeny-dependent differences in dopaminergic systems. Thus, my research objectives were to investigate the contributions of the neuronal nitric oxide synthase (nNOS) gene, ontogeny, and gender on the rewarding and sensitizing effects of cocaine. I found that nNOS significantly influences the rewarding aspects of cocaine in adolescent mice and adult male mice (i.e., major deficits in several phases of cocaine conditioned place preference (CPP) were detected in nNOS knockout (KO) adolescent mice and nNOS KO adult male mice). However, the contribution of nNOS was sex-dependent as CPP phases were normal in KO adult females. In contrast to CPP, I found a major ontogeny-dependent contribution of nNOS to the sensitizing effects of cocaine. Namely, while nNOS is essential for the development of behavioral sensitization in adult males, this type of behavioral plasticity develops independently of nNOS during adolescence. The contribution of nNOS was once again sex-dependent as behavioral sensitization was normal in adult KO females. Together, this line of investigation has revealed that the NO-signaling pathway has a) a sex-dependent role in the neuroplasticity underlying cocaine CPP and b) a sex-dependent and ontogeny-dependent influence on cocaine-induced behavioral sensitization. Stereological and western blot analysis revealed that a sensitizing regimen of cocaine resulted in an increase in nNOS and tyrosine hydroxylase (TH) immunoreactivity in the dorsal striatum (dST) of adult, but not adolescent, wild-type (WT) male mice. In the absence of nNOS, dopaminergic neurons in the ventral tegmental area (VTA) were severely reduced and cocaine caused a downregulation of dST TH suggesting that nitrergic levels modulate TH. Thus, the finding that nNOS is essential for the development of sensitization in adulthood, but not adolescence, together with the fact that cocaine upregulated nNOS and TH in the dST in adult, but not adolescent mice, strongly suggest that the nitrergic system underlies behavioral sensitization through modulation of the dopaminergic system in adulthood. These findings suggest different approaches in the clinical treatment of drug craving and drug-seeking behavior in adolescent and adult patients.

Binge alcohol consumption is a rising concern in the United States, especially among adolescents as during this developmental period alcohol use is usually initiated and has been shown to cause detrimental effects on brain structure and function. These findings have been established through the use of binge models in animals, where animals are repeatedly administered high doses of ethanol typically over a period of three or four days. While such work has examined the effects of a four-day and repeated three-day binge, there has been almost no work conducted aimed at investigating the long-term behavioral and neurochemical and/or functional consequences of repeated binge pattern administration during adolescence relative to adulthood on later ethanol-induced behavior and neurochemistry in adulthood. The present set of experiments aimed to examine the dose-response and age-related differences induced by repeated binge pattern ethanol administration during adolescence or adulthood on voluntary ethanol consumption (Aim 1), changes in ethanol metabolism following ethanol pretreatment (Aim 2) and mesolimbic dopamine functionality (Aim 3) in adulthood. In both experiments, adolescent and adult male rats were intragastrically administered ethanol (0.5, 1.0 or 2.0 g/kg/ig) or isovolumetric water on postnatal days (PND) 28-31, PND 35-38 and PND 42-45 for adolescent rats and PND 60-64, PND 67-70 and PND 74-77 for adult rats. In both experiments all rats underwent fourteen days of abstinence (PND 46-59 or PND 78-91, respectively). Subsequently, in Experiment 1, all rats underwent voluntary ethanol consumption procedures, in which animals were exposed to 10% ethanol combined with decreasing saccharin concentrations across days from PND 60-82 for adolescent-exposed rats and PND 92-114 for adult-exposed rats. Finally, on PND 83 and PND 115, respectively, all animals were challenged with 2.0 g/kg ethanol and trunk blood samples were collected at 60 and 240 minutes post-injection. Results indicate there was a significant increase in voluntary ethanol intake in adolescent ethanol-exposed rats pretreated with 2.0 g/kg relative to their adult ethanol-pretreated counterparts. Faster ethanol metabolism was observed in adolescent rats pretreated with 2.0 g/kg during adolescence relative to adolescent-exposed rats pretreated with 0.5 g/kg and adults pretreated with 2.0 g/kg. For Experiment 2, all rats underwent surgery (PND 60 for adolescent-exposed and PND 92 for adult-exposed rats). From PND 61-64 for adolescent-exposed and PND 93-96 for adult exposed rats, all animals underwent recovery from surgery. Finally, all rats underwent in vivo microdialysis on PND 65 for adolescent-exposed and PND 97 for adult-exposed rats, with K+ (100 mM) infused into the ventral tegmental area and accumbal dopamine overflow assessed in the nucleus accumbens septi. The results from Experiment 2 indicate lasting changes in mesolimbic dopamine functionality with a trend for decreased potassium-stimulated dopamine overflow in the nucleus accumbens septi in adolescent-ethanol pretreated rats and a trend for increased potassium-stimulated dopamine overflow in adult ethanol-pretreated rats. The results from the present set of experiments show the dose-dependent impact of binge-pattern ethanol exposure during adolescence on subsequent ethanol consumption and ethanol metabolism in adulthood. These findings indeed determine adolescence as a period of vulnerability to the long-term changes in ethanol consumption relative to similarly-exposed adult male rats. Importantly, the results of Experiment 2 indicate an alteration in the functionality of the mesolimbic pathway in adulthood following adolescent binge pattern ethanol exposure, which demonstrates a long-term depression in mesolimbic dopamine functionality following adolescent binge pattern ethanol exposure.

The aim of the current study was divided into two separate goals, (i) optimization of a number of PCR-based protocols employed for genotyping transgenic mouse lines and (ii) evaluating a protocol for co-detection of mRNA and its correlated protein in the mouse midbrain. The optimization was performed on PCR protocols for genotyping the following transgenic mouse lines; Dat-Cre, Vglut2-Lox, Vglut2-Cre and Vmat2-Lox. Also, two different polymerases were evaluated parallel to each other – KAPA and Maxima Hot Start. One of the main findings from the PCR optimizations were that for the Vglut2-Lox protocol. By decreasing the annealing temp and increasing the MgCl2 the bands appeared brighter.  For the second part of the project, in-situ hybridization (ISH) was used to detect the mRNA expression with a `non-radioactive in situ hybridization´ protocol, using digoxigenin or fluorescein labelled riboprobes (mRNA probes). To detect the correlated protein a basic immunohistochemistry (IHC) protocol with the use of primary and secondary antibodies was implemented. The combined protocol was tested with Nd6 and Grp markers. Before testing to combined the protocols the ISH protocol was performed alone with riboprobes for Girk2, Lpl and Fst. The combined protocol detected mRNA and protein for both the control marker Th and the Nd6 marker. In conclusions, the optimized PCR protocols were optimal when used with the Maxima Hot Start polymerase and the new combined ISH and IHC protocol worked for markers Th and Nd6.

Alcohol use disorder is a debilitating disorder affecting nearly 5% of people in the United States. Despite the prevalence of alcohol use disorder few affected individuals seek treatment and of those who do many will relapse. This highlights a need to develop new treatments for alcohol use disorder that are both more accessible and more effective. This dissertation characterizes a novel pathway involved in ethanol enhancement of dopamine levels in the nucleus accumbens as well as investigating alterations in dopamine 2 receptor expression and function following an acute dose of ethanol. This was done by using microdialysis to measure dopamine levels in the nucleus accumbens, single-unit recordings of dopamine neurons in the ventral tegmental area to measure dopamine neuron activity and place conditioning to measure the rewarding properties of the intravenous dopamine and ethanol. It was found that activation of peripheral dopamine 2 receptors by intravenous dopamine enhanced dopamine levels in the nucleus accumbens and dopamine neuron firing rate in the ventral tegmental area. Additionally, intravenous dopamine produced a modest conditioned place preference. Domperidone, a peripheral dopamine 2 receptor antagonist blocked each of these effects. Further, domperidone blocked ethanol enhancement of dopamine release in the nucleus accumbens and bidirectionally modulated the sedating effects of ethanol depending on the dose of ethanol administered. The involvement of peripheral dopamine 2 receptors in ethanol reward could not be ascertained in these studies as domperidone produced a weak conditioned place aversion. Finally, acute ethanol was found to enhance dopamine 2 receptor expression in the nucleus accumbens and medial prefrontal cortex while also enhancing dopamine 2 receptor expression on NK and B cells. Additionally, ethanol was found to reduce desensitization of dopamine 2 receptors in the ventral tegmental area. These results demonstrate that activation of peripheral dopamine 2 receptors can enhance dopamine levels in the nucleus accumbens and that this effect has relevance in understanding the effects of ethanol on dopamine release in the mesolimbic pathway. These results also provide evidence for transient upregulation of dopamine 2 receptors in the brain and on leukocytes suggesting that dopamine 2 receptor levels on leukocytes may be a useful biomarker for central dopamine function.

Alcohol use disorder is a debilitating disorder affecting nearly 5% of people in the United States. Despite the prevalence of alcohol use disorder few affected individuals seek treatment and of those who do many will relapse. This highlights a need to develop new treatments for alcohol use disorder that are both more accessible and more effective. This dissertation characterizes a novel pathway involved in ethanol enhancement of dopamine levels in the nucleus accumbens as well as investigating alterations in dopamine 2 receptor expression and function following an acute dose of ethanol. This was done by using microdialysis to measure dopamine levels in the nucleus accumbens, single-unit recordings of dopamine neurons in the ventral tegmental area to measure dopamine neuron activity and place conditioning to measure the rewarding properties of the intravenous dopamine and ethanol. It was found that activation of peripheral dopamine 2 receptors by intravenous dopamine enhanced dopamine levels in the nucleus accumbens and dopamine neuron firing rate in the ventral tegmental area. Additionally, intravenous dopamine produced a modest conditioned place preference. Domperidone, a peripheral dopamine 2 receptor antagonist blocked each of these effects. Further, domperidone blocked ethanol enhancement of dopamine release in the nucleus accumbens and bidirectionally modulated the sedating effects of ethanol depending on the dose of ethanol administered. The involvement of peripheral dopamine 2 receptors in ethanol reward could not be ascertained in these studies as domperidone produced a weak conditioned place aversion. Finally, acute ethanol was found to enhance dopamine 2 receptor expression in the nucleus accumbens and medial prefrontal cortex while also enhancing dopamine 2 receptor expression on NK and B cells. Additionally, ethanol was found to reduce desensitization of dopamine 2 receptors in the ventral tegmental area. These results demonstrate that activation of peripheral dopamine 2 receptors can enhance dopamine levels in the nucleus accumbens and that this effect has relevance in understanding the effects of ethanol on dopamine release in the mesolimbic pathway. These results also provide evidence for transient upregulation of dopamine 2 receptors in the brain and on leukocytes suggesting that dopamine 2 receptor levels on leukocytes may be a useful biomarker for central dopamine function.

Rationale: There is evidence for a common genetic link between alcohol and nicotine dependence. Rodents selectively bred for high alcohol consumption/responsivity are also more likely to self-administer nicotine than controls. Objectives: The experiments examined the response to systemic nicotine, the effects of nicotine within the drug reward pathway, and innate expression of nicotine-related genes in a brain region regulating drug reward/self-administration in multiple lines of rats selectively bred for high and low alcohol consumption. Methods: The experiments examined the effects of systemic administration of nicotine on locomotor activity, the effects of nicotine administered directly into the (posterior ventral tegmental area; pVTA) on dopamine (DA) release in the nucleus accumbens shell (AcbSh), and innate mRNA levels of acetylcholine receptor genes in the pVTA were determined in 6 selectively bred high/low alcohol consuming and Wistar rat lines. Results: The high alcohol-consuming rat lines had greater nicotine-induced locomotor activity compared to low alcohol-consuming rat lines. Microinjections of nicotine into the pVTA resulted in DA release in the AcbSh with the dose response curves for high alcohol-consuming rats shifted leftward and upward. Genetic analysis of the pVTA indicated P rats expressed higher levels of α2 and β4. Conclusion: Selective breeding for high alcohol preference resulted in a genetically divergent behavioral and neurobiological sensitivity to nicotine. The observed behavioral and neurochemical differences between the rat lines would predict an increased likelihood of nicotine reinforcement. The data support the hypothesis of a common genetic basis for drug addiction and identifies potential receptor targets.

La course d’endurance active le système de récompense (SR) et est reliée aux comportements de recherche alimentaire. L’influence de la leptine sur l’activité physique (AP) volontaire est bien documentée d’un point de vue physiologique, mais très peu en termes d’impact hédonique. La leptine inhibe l’effet récompensant lié à la consommation de nourriture et joue un rôle semblable pour d’autres types de stimuli. La leptine s’arrime à la forme longue du récepteur à la leptine (Leprb) situé sur les neurones à dopamine (DA) et GABA de l’aire tegmentale ventrale (ATV) dans le mésencéphale. Signal transducer and Activator of Transcription 3 (STAT3) est un facteur de transcription important de la cascade de signalisation de la leptine. La phosphorylation de STAT3 n’est détectée que dans une parcelle des neurones DA positifs pour le Leprb, conférant aux neurones DA STAT3-spécifiques des caractéristiques uniques. Nous avons généré un modèle murin invalidé pour STAT3 sélectivement dans les neurones DA (STAT3DAT-KO). La première expérience consistait à évaluer les paramètres métaboliques de base de notre modèle en utilisant les chambres métaboliques Comprehensive Lab Animal Monitoring System (CLAMS), incluant l’activité ambulatoire, le ratio d’échanges respiratoires (RER) et la production de chaleur. Les STAT3DAT-KO sont hyperactives, démontré par une activité locomotrice augmentée, mais aucune variation entre les deux groupes n’est observée pour le RER et la production de chaleur, en plus d’un gain de poids identique. Une stratégie de récupération ciblant la réinsertion de STAT3 dans les neurones DA du système mésolimbique normalise l’AP anciennement plus élevée des STAT3DAT-KO à celle des contrôles, suivant l’accès libre à une roue d’exercice (RE) pour une durée de 4 semaines, suivant l’accès libre à une roue d’exercice (RE) pour une durée de 4 semaines. L’injection d’un psychostimulant (agoniste du récepteur DA de type 1 (D1R), le Chloro-APB-Hydrobromide (SKF 82958)) reflète une fonction dopaminergique réduite chez les STAT3DAT-KO. Un test de recherche compulsive de nourriture révèle une suppression de la prise alimentaire chez les deux groupes expérimentaux. Nous démontrons pour la première fois que la motivation alliée à la course d’endurance, indépendamment de la régulation de la prise alimentaire par la leptine, est dépendant d’une signalisation leptine-STAT3 amoindrie dans les neurones DA du système mésolimbique, révélant STAT3 comme élément clé dans la régulation du tonus dopaminergique et des propriétés récompensantes de l’AP. / Endurance running is rewarding and related to food seeking behaviors. Influence of leptin on voluntary physical activity is well documented from a physiological point of view, but little is known about its hedonic impact. Leptin inhibits the rewarding aspects of food consumption and plays a similar role for other types of stimuli. Leptin binds to the long form of the leptin receptor, situated on dopamine (DA) and GABA neurons of the ventral tegmental area (VTA) in the midbrain. Signal Transducer and Activator of Transcription 3 (STAT3) is an important transcription factor of the leptin signalling cascade. Phosphorylation of STAT3 is detected only in a subset of neurons that are positive for the leptin receptor, conferring unique properties to DA STAT3 neurons. We generated a mouse model invalidated for STAT3 selectively in dopamine neurons (STAT3DAT-KO). We first assessed basic metabolic parameters of our model using CLAMS metabolic chambers, including ambulatory acitivity, respiratory exchange ratio (RER) and heat production. STAT3DAT-KO are hyperactive as seen by a higher locomotor activity, but there is no inter-group variation of RER and heat production, and the weight gain is the same. A rescue strategy targeting the reinsertion of STAT3 in DA neurons of the mesolimbic system normalizes physical activity of the STAT3DAT-KO - which was previously much higher - to that of the control mice, following free access to a running wheel for a period of 4 weeks. The injection of a psychostimulant (agonist of the type1 DA receptor (D1R), Chloro-APB-Hydrobromide (SKF 82958)) reflects a reduced DA signalling STAT3DAT-KO. A compulsive food seeking test reveals a suppression of sucrose intake in both experimental groups. We demonstrate for the first time that the motivation allied to endurance running, independently of food intake regulation by leptin, is dependent upon a diminished leptin-STAT3 signalling in DA neurons of the midbrain, revealing STAT3 as a key player in the regulation of DA tone and the rewarding properties of physical activity.

La queue de l’aire tegmentale ventrale (tVTA) est le principal contrôle inhibiteur des neurones dopaminergiques du mésencéphale. Cette structure, bien qu’aujourd’hui très étudiée, n’est cependant pas encore référencée dans les atlas stéréotaxiques. Anatomiquement, nous avons pu apporter une définition de référence de la tVTA, à travers son analyse neurochimique, stéréologique, hodologique et génomique. Fonctionnellement, nous avons montré son rôle dans la réponse à des expériences émotionnelles aversives et nous avons testé son influence sur les symptômes moteurs et non-moteurs de la maladie de Parkinson. Nous avons ainsi montré qu’une co-lésion de la tVTA dans un modèle murin de la maladie permet une amélioration des performances motrices, des seuils nociceptifs et des symptômes de type dépressifs. Ce travail a ainsi participé au progrès de nos connaissances sur la tVTA et ouvre de nouvelles pistes d’exploration quant à son implication fonctionnelle. / The tail of the ventral tegmental area (tVTA) is the major brake of the midbrain dopamine neurons. This structure although studied, is not yet referenced in stereotaxic atlases. Anatomically, this work allowed to obtain a reference definition of the tVTA through its neurochemical, stereological, connectivity-based and genomic analyses. Functionally, we studied its role for the response of aversive stimuli and we tested its influence on motor and non-motor symptoms of Parkinson’s disease. We observed that a co-lesion of the tVTA in a rodent model of the disease induce motor, nociceptive and depressive-like symptoms improvements. This work has thus contributed to the progress of our knowledge on the tVTA and opens new explorative track for its functional implication.